Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
- PMID: 1778894
- DOI: 10.1093/jac/28.suppl_b.73
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
Abstract
One hundred and twenty-six patients were treated for 137 episodes of fungal infection with liposomal amphotericin B (AmBisome) at 43 investigational centres. Among the patients were 72 with malignancies, 17 organ transplant recipients, 20 patients with immunological disorders and 17 others. AmBisome treatment was instituted after toxicity from previous amphotericin B treatment in 49 cases, nephrotoxicity or renal insufficiency in 40 and failure of previous antifungal treatment in 41. One hundred and eight episodes were clinically evaluable; among these 52 were caused by Candida spp. and 34 by Aspergillus spp. Ninety-nine patients were treated for at least eight days with a maximum dose of 0.7-5 mg/kg/day. Among 64 cases with proven invasive fungal infection 58% were cured. Fungi were eradicated in 35 of 54 (65%) mycologically evaluable cases. The cumulative dose was 3.2 +/- 3.2 (mean +/- S.D.) in cases where fungi were eradicated in comparison with 3.3 +/- 2.3 g in cases where fungi persisted. The eradication rate was 83% for Candida spp. compared with 41% for Aspergillus spp. (P less than 0.01). Among 24 cases with presumptive invasive fungal infections 14 (58%) were cured. Candida spp. were eradicated in seven of ten of these cases. Among 11 cases with superficial fungal infections eight were cured and three improved. Candida spp. were eradicated in four of five patients. It is concluded that AmBisome is an effective antifungal agent in a majority of patients with invasive or superficial fungal infections.
Similar articles
-
Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children.Mycoses. 1993 May-Jun;36(5-6):187-92. doi: 10.1111/j.1439-0507.1993.tb00748.x. Mycoses. 1993. PMID: 8264715
-
Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.Arch Intern Med. 1995 May 22;155(10):1093-8. Arch Intern Med. 1995. PMID: 7748054
-
A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients.Mycoses. 1992 Sep-Oct;35(9-10):215-20. doi: 10.1111/j.1439-0507.1992.tb00850.x. Mycoses. 1992. PMID: 1291871
-
Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.Drugs. 1998 Apr;55(4):585-612. doi: 10.2165/00003495-199855040-00008. Drugs. 1998. PMID: 9561346 Review.
-
Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.Clin Microbiol Infect. 2001;7 Suppl 2:68-79. doi: 10.1111/j.1469-0691.2001.tb00012.x. Clin Microbiol Infect. 2001. PMID: 11525221 Review.
Cited by
-
Two Types of Liposomal Formulations Improve the Therapeutic Ratio of Prednisolone Phosphate in a Zebrafish Model for Inflammation.Cells. 2022 Feb 15;11(4):671. doi: 10.3390/cells11040671. Cells. 2022. PMID: 35203318 Free PMC article.
-
Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.Infect Dis Ther. 2021 Mar;10(1):115-147. doi: 10.1007/s40121-020-00382-7. Epub 2021 Feb 1. Infect Dis Ther. 2021. PMID: 33523419 Free PMC article. Review.
-
Development of Amphotericin B Micellar Formulations Based on Copolymers of Poly(ethylene glycol) and Poly(ε-caprolactone) Conjugated with Retinol.Pharmaceutics. 2020 Feb 25;12(3):196. doi: 10.3390/pharmaceutics12030196. Pharmaceutics. 2020. PMID: 32106492 Free PMC article.
-
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076. Clin Infect Dis. 2019. PMID: 31222253 Free PMC article. Review.
-
Invasive Aspergillosis in Children: Update on Current Guidelines.Mediterr J Hematol Infect Dis. 2018 Sep 1;10(1):e2018048. doi: 10.4084/MJHID.2018.048. eCollection 2018. Mediterr J Hematol Infect Dis. 2018. PMID: 30210741 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous